Search Results
Dec 15, 2025, 08:00 ET Kenai Therapeutics Announces First Patient Dosed in Phase 1 REPLACE™ Clinical Trial of Neuron Replacement Cell Therapy RNDP-001 for Idiopathic Parkinson's Disease
Dynamics utilizes its iPSC platform to advance the progress of therapeutic candidates in the clinic and provides contract development and manufacturing (CDMO) services. In addition to cell therapy, FUJIFILM Cellular Dynamics also offers life science research tools including the company's inventoried iCell®
More news about: Kenai Therapeutics/BIOCOM
Dec 15, 2025, 01:28 ET Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.
fulfilment of regulatory and performance milestones. In addition, Arthrosi has also entered into new statement of work (SOW) with the Viva Biotech's CDMO business unit (Langhua Pharmaceutical) for the supply of active pharmaceutical ingredient, and the Group expects to continue its business cooperation
More news about: Viva Biotech
Dec 15, 2025, 01:06 ET Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.
fulfilment of regulatory and performance milestones. In addition, Arthrosi has also entered into new statement of work (SOW) with the Viva Biotech's CDMO business unit (Langhua Pharmaceutical) for the supply of active pharmaceutical ingredient, and the Group expects to continue its business cooperation
More news about: Viva Biotech
Dec 15, 2025, 01:00 ET Piramal Pharma Solutions Demonstrates Commitment to Excellence with Outstanding Net Promoter Score
Dec. 15, 2025 /PRNewswire/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), has achieved an impressive Net Promoter Score (NPS) of 55 for the time period
More news about: Piramal Pharma Solutions
Dec 15, 2025, 00:49 ET Piramal Pharma Solutions Demonstrates Commitment to Excellence with Outstanding Net Promoter Score
Dec. 15, 2025 /PRNewswire/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), has achieved an impressive Net Promoter Score (NPS) of 55 for the time period
More news about: Piramal Pharma Solutions
Dec 12, 2025, 09:00 ET KVP International übernimmt SafePath Laboratories und IVD Research und erweitert damit seine Kompetenzen im Bereich Diagnostik
diagnostische Produkte spezialisierte Hersteller SafePath-IVD wird als Forschungs-, Entwicklungs- und Produktionspartner von KVP fungieren und gleichzeitig sein CDMO-Diagnostikgeschäft weiter ausbauen.MCKINNEY, Texas, 12. Dezember
More news about: KVP International
Dec 12, 2025, 09:00 ET KVP International Acquires SafePath Laboratories and IVD Research, Expanding Its Capabilities in Diagnostics
California–based diagnostics manufacturer, SafePath-IVD, to serve as KVP's research, development and manufacturing partner while continuing to grow its CDMO diagnostics business.MCKINNEY, Texas, Dec. 12, 2025 /PRNewswire/
More news about: KVP International
Dec 12, 2025, 09:00 ET KVP International acquiert SafePath Laboratories et IVD Research, élargissant ainsi ses capacités dans le domaine du diagnostic
pour la recherche, le développement et la fabrication tout en continuant à développer son activité de développement et de fabrication sous contrat (CDMO) pour les diagnostics.MCKINNEY, Texas, 12 décembre 2025
More news about: KVP International
Dec 11, 2025, 08:00 ET Lindus Health and Quotient Sciences Partner to Accelerate Drug Development from First-in-Human to Pivotal Trials
therapeutic solutions, fast. Quotient Sciences has been recognised as a multi-year winner of the CRO Leadership Awards in 2021, 2022, and 2024 and of the CDMO Leadership Awards in 2023. For more information, visit quotientsciences.com.Press Contact:Jodi PerkinsAmendola Communications
More news about: Lindus Health
Dec 10, 2025, 18:30 ET Samsung Biologics recognized as a global leader in water security
Dec. 10, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced that it has received from the Carbon Disclosure Project (CDP) an 'A' rating in Water Security.
More news about: Samsung Biologics
Dec 09, 2025, 09:16 ET Akadeum Life Sciences Announces Establishment of the Akadeum CDMO Alliance Program
patients," said Ahmad Hussin, Charles River Vice President, CDMO, Charles River. "We are excited to join Akadeum's CDMO Alliance, expanding the range of capabilities we're able to offer our clients." Benefits to Akadeum CDMO Alliance Members
More news about: Akadeum Life Sciences
Dec 09, 2025, 08:39 ET Bora Pharmaceuticals and Corealis Pharma Forge Strategic Alliance to Deliver Seamless, End-to-End Oral Solid Dose Development
capability and culture," said J.D. Mowery, President of Bora's CDMO division. "By combining Bora's scale-up strength with Corealis' early-phase expertise, and leveraging the reliability of both organizations, we're setting a new standard for CDMO collaboration."The companies will align project management
More news about: Bora Pharmaceuticals
Dec 08, 2025, 08:34 ET GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program
clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced that it has entered into a CDMO service agreement with the
More news about: GlycoNex, Inc.
Dec 08, 2025, 08:00 ET Andelyn Biosciences Announces Partnership with Jaguar Gene Therapy to Provide Late-Stage PPQ Manufacturing
patient-first approach, Andelyn continues to serve as the CDMO partner of choice for organizations advancing life-changing gene therapies.About Andelyn Biosciences, Inc.Andelyn Biosciences is a full-service cell and gene therapy CDMO focused on the development, characterization, and production
More news about: Andelyn Biosciences
Dec 08, 2025, 00:00 ET AsymBio Commences Commercial Operations at Fengxian Base, Strengthening Global Biopharmaceutical CDMO Capabilities
AsymBio, a technology-driven global Contract Development and Manufacturing Organization (CDMO) and a subsidiary of
More news about: Shanghai Asymchem Biotechnology Co., Ltd.
Dec 05, 2025, 05:49 ET mAbxience e HP danno impulso all'uso dell'intelligenza artificiale nella bioproduzione e nello sviluppo di biosimilari
tecnologica, questa soluzione racchiude un potenziale di trasformazione per tutti i partner mAbxience – sia licenziatari di biosimilari sia clienti CDMO. Integrando l'IA nelle operazioni di produzione, mAbxience punta a ottimizzare significativamente il suo approccio allo sviluppo di prodotti biologici,
More news about: mAbxience
Dec 05, 2025, 05:37 ET mAbxience und HP treiben den Einsatz künstlicher Intelligenz bei der Bioproduktion und der Entwicklung von Biosimilars voran
die technologische Innovation hinaus birgt diese Lösung für alle Partner von mAbxience, sowohl für die Lizenznehmer von Biosimilars als auch für CDMO-Kunden, ein transformatives Potenzial. Durch die Integration von KI in seine Produktionsabläufe will mAbxience seinen Ansatz zur Entwicklung von Biologika
More news about: mAbxience
Dec 04, 2025, 09:00 ET Quotient Sciences and Intrepid Labs form strategic partnership to accelerate AI-guided formulation development
therapeutic solutions, fast. Quotient Sciences has been recognized as a multi-year winner of the CRO Leadership Awards in 2021, 2022, and 2024 and of the CDMO Leadership Awards in 2023.Intrepid LabsIntrepid Labs is the AI leader in pharmaceutical formulation science, dedicated to designing
More news about: Quotient Sciences
Dec 04, 2025, 07:59 ET mAbxience et HP encouragent l'utilisation de l'intelligence artificielle dans la biofabrication et le développement de biosimilaires
solution présente un potentiel de transformation pour tous les partenaires de mAbxience, qu'il s'agisse de licenciés de biosimilaires ou de clients CDMO. En intégrant l'IA dans ses opérations de fabrication, mAbxience vise à optimiser de manière significative son approche en matière de développement des
More news about: mAbxience
Dec 04, 2025, 04:26 ET mAbxience y HP impulsan el uso de la inteligencia artificial en la biomanufactura y el desarrollo de biosimilares
tecnológica, esta solución tiene un potencial transformador para todos los socios de mAbxience, tanto licenciatarios de biosimilares como clientes CDMO. Al integrar la IA en sus operaciones de fabricación, mAbxience busca optimizar significativamente su enfoque de desarrollo hacia los biológicos, mejorando
More news about: mAbxience
Dec 04, 2025, 03:00 ET mAbxience and HP drive the use of artificial intelligence in biomanufacturing and biosimilar development
HP.Beyond its technological innovation, this solution holds transformational potential for all of mAbxience's partners, both biosimilar licensees and CDMO clients. By integrating AI into its manufacturing operations, mAbxience aims to significantly optimize its development approach towards biologics development,
More news about: mAbxience
Dec 04, 2025, 03:00 ET mAbxience and HP drive the use of artificial intelligence in biomanufacturing and biosimilar development
HP.Beyond its technological innovation, this solution holds transformational potential for all of mAbxience's partners, both biosimilar licensees and CDMO clients. By integrating AI into its manufacturing operations, mAbxience aims to significantly optimize its development approach towards biologics development,
More news about: mAbxience
Dec 03, 2025, 09:00 ET Benuvia Operations Announces Strategic Partnership with Cannovation Clinical Research Partners to Deliver Fully Integrated Solutions for Controlled-Substance Therapeutics
medicines."About Benuvia Operations, LLCBenuvia Operations, LLC is a U.S.-based global Contract Development and Manufacturing Organization (CDMO) and Active Pharmaceutical Ingredient (API) supplier servicing pharmaceutical and biotech companies. The company provides development and manufacturing
More news about: Benuvia Operations, LLC
Dec 02, 2025, 10:18 ET Cellipont Bioservices Expands Manufacturing Capabilities with New Ballroom-style Cleanroom and 50-liter Single-use Bioreactor to Advance Cell Therapy Production
Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced the completion of its ballroom-style cleanroom, featuring a state-of-the-art 50-liter single-use bioreactor. This facility expansion
More news about: Cellipont Bioservices
Dec 02, 2025, 08:50 ET Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances
thousand, compared to $1,964 thousand as of September 30, 2024.Business UpdateCDMO Business - Scinai BioservicesScinai Bioservices continues to expand its role as a boutique CDMO serving early-stage biotech companies in Israel, the United States, and Europe.The
More news about: Scinai Immunotherapeutics Ltd.